MOS-J / MOS-J-luc Orthotopic Mouse Model Service for Sarcoma

The MOS-J / MOS-J-luc orthotopic mouse model for sarcoma is a syngeneic, immune-competent platform in which murine osteosarcoma cells are grafted directly into the bone — typically the tibia — of C57BL/6 hosts, reproducing bone destruction, vascular invasion, and spontaneous spread to the lung within a fully intact immune system. Alfa Cytology delivers this model as a complete preclinical capability — covering authenticated MOS-J / MOS-J-luc expansion and luciferase-stable banking, precision intraosseous or paratibial implantation, scheduled in vivo bioluminescence tracking of primary bone tumors and pulmonary lesions, and full skeletal histopathology — all configured around each sponsor’s agent class, dosing schedule, and endpoint plan.

Overview of MOS-J / MOS-J-luc Orthotopic Mouse Model for Sarcoma

MOS-J is a murine osteosarcoma line whose pedigree makes it one of the most naturalistic sarcoma models available. It was established at The Jackson Laboratory and described in 2002 by Joliat and colleagues from a spontaneously arising chondroblastic osteosarcoma in the distal right femur of an aged female C57BL/6J mouse — meaning the line carries the molecular history of a bone tumor that developed endogenously rather than one induced by chemical or radiation insult. In vitro, MOS-J cells are pleomorphic and mitotically active, display marked alkaline phosphatase activity, deposit mineralized matrix that stains with alizarin red, and potently promote osteoclast differentiation from normal bone marrow cells. In vivo, the line forms solid tumors in immunocompetent syngeneic hosts while mimicking endochondral bone development; the resulting masses destroy and invade adjacent cortical bone and encroach on nearby vasculature — the two pathological hallmarks of human osteosarcoma. When introduced paratibially or intraosseously, MOS-J cells build primary tumors with a frankly osteogenic phenotype, and orthotopic primaries give rise to spontaneous pulmonary metastasis.

Fig 1. MOS-J syngeneic model: tumor volume curves under macitentan (10/30 mg/kg) vs control with tibial X-ray images showing osteoblastic lesion formation (red arrows). (Muñoz-Garcia, Javier, et al., 2022)

Because the host is the syngeneic C57BL/6 mouse, the MOS-J orthotopic system runs with a fully competent immune compartment — a decisive advantage for immuno-oncology programs that human xenografts cannot offer. The luciferase-tagged derivative MOS-J-luc adds quantitative visibility: engraftment in the operated limb, primary tumor expansion, and the emergence of lung metastases can all be tracked longitudinally by in vivo bioluminescence after luciferin administration, with ex vivo thoracic imaging at necropsy confirming metastatic burden. The platform has proven itself across bone-biology questions (osteoclastogenesis and the RANKL/RANK axis), cancer-cell dormancy and relapse at the bone site, combination immunotherapy, and anti-metastatic screening — and, as with human disease, surgical removal of the primary limb tumor can be incorporated to allow time for metastatic disease to declare itself.

Cell Line Information: MOS-J / MOS-J-luc

The table below consolidates the key biological, cultural, and modeling characteristics of the MOS-J parental line and its luciferase-labeled derivative MOS-J-luc. Both are murine and syngeneic to C57BL/6 hosts, so full immune competence is retained throughout.

Our Services

Executing a bone-orthotopic sarcoma study well requires orthopedic-grade microsurgery and quantitative imaging discipline in equal measure, and Alfa Cytology brings both: validated MOS-J / MOS-J-luc banks, reproducible intratibial implantation with consistent take rates, weekly in vivo bioluminescence schedules, and metastasis-focused skeletal pathology — delivered as a single accountable preclinical program.

Workflow of MOS-J / MOS-J-luc Orthotopic Mouse Model Construction

Construction follows established intraosseous grafting methodology: luciferase-labeled MOS-J cells are expanded under authenticated conditions, formulated as a concentrated suspension, implanted into the medullary cavity of the proximal tibia (or onto the periosteum for the paratibial variant) of syngeneic C57BL/6 mice, and followed by serial imaging with bone-focused endpoint analysis. The workflow comprises the following stages.

1. Cell authentication and banking: MOS-J or MOS-J-luc cells are confirmed mycoplasma-free, profiled for identity, and expanded into low-passage working banks under standardized complete-medium culture conditions.
2. Cell harvest and formulation: Healthy adherent cultures are trypsinized, washed, counted and viability-checked, then resuspended at the study-specified dose of approximately 1–4 × 10⁶ cells in 10–20 μL of PBS or a Matrigel-supported suspension and kept on ice until implantation.
3. Anesthesia and tibial preparation: Mice are anesthetized with isoflurane, the hair over the proximal tibia is clipped, and a small skin incision exposes the tibial plateau; for the intraosseous route, a fine entry hole is made through the cortex at the medial tibial plateau.
4. Orthotopic implantation: The cell suspension is slowly injected into the medullary cavity beneath the tibial plateau (or deposited onto the scraped periosteum for paratibial grafting); the tract is sealed and the needle held briefly to limit reflux along the injection channel.
5. Closure and perioperative care: The cortical entry is sealed, the skin is closed with sutures or wound clips, and animals receive analgesia with close post-operative monitoring, including gait observation for lameness and limb swelling.
6. Engraftment verification and serial imaging: Luciferin is administered intraperitoneally and bioluminescence is acquired to confirm take in the operated limb; imaging repeats on a weekly cadence to track primary bone tumor growth and flag emerging thoracic metastatic signal.
7. Intervention and endpoint analysis: Experimental arms — chemotherapy, RANKL/RANK-pathway blockade, immune checkpoint and combination regimens, or radiation — proceed per study design; endpoints integrate imaging with limb caliper measurements, micro-CT analysis of cortical destruction and new bone formation, ex vivo lung bioluminescence, and histopathology (H&E with Ki67, TRAP, and osteosarcoma-marker immunohistochemistry).

Fig 2. MOS-J / MOS-J-luc orthotopic mouse model construction workflow.

Case Study-MOS-J / MOS-J-luc Orthotopic Mouse Model Development

Alfa Cytology has conducted preclinical programs on the MOS-J / MOS-J-luc orthotopic platform spanning bone-biology intervention, immunotherapy combination evaluation, and anti-metastatic agent screening. In these studies, intratibially implanted MOS-J-luc tumors were longitudinally quantified by in vivo bioluminescence, with primary bone destruction and pulmonary metastatic burden characterized at endpoint by imaging, micro-CT, and histopathology. Program-level datasets are available upon request.

Why Choose Alfa Cytology?

Alfa Cytology combines bone-tumor microsurgical expertise with quantitative imaging and skeletal pathology in one integrated system, so every MOS-J / MOS-J-luc orthotopic study is executed with reproducible technique and reporting quality sponsors can stand behind.

• Focused experience with syngeneic, immune-competent osteosarcoma models and bone-orthotopic study designs, including paratibial and intraosseous routes.
• A single coordinated team managing cell banking, orthopedic implantation surgery, in vivo imaging, micro-CT, and endpoint pathology under one quality framework.
• Longitudinal bioluminescence readouts covering primary bone growth and early pulmonary metastatic emergence.
• Flexible intervention arms spanning chemotherapy, RANKL/RANK-pathway blockade, checkpoint immunotherapy, and radiation.
• Transparent milestone reporting and rapid scientific feedback throughout the engagement.

Contact Us

If your sarcoma program needs a bone-faithful, immune-competent orthotopic platform with bioluminescent metastasis tracking, Alfa Cytology is ready to support you. Reach out to us with your study objectives and endpoint requirements, or contact us today for a customized proposal and quotation for the MOS-J / MOS-J-luc orthotopic mouse model service.

For research use only. Not intended for any clinical use.